Inhibition of SARS-CoV-2 Omicron BA.1 and BA.4 Variants After Fourth Vaccination or Tixagevimab and Cilgavimab Administration in Patients With Cancer.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2022.4226
Abstract: This cohort study assesses the capacity of passive immunization and tixagevimab and cilgavimab to inhibit interaction between receptor-binding domains and angiotensin-converting enzyme 2 in patients with hemato-oncologic diseases. read more here.
Keywords: tixagevimab; inhibition sars; tixagevimab cilgavimab; omicron variants ... See more keywords
Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence
Sign Up to like & getrecommendations! Published in 2023 at "Expert Opinion on Drug Discovery"
DOI: 10.1080/17460441.2023.2170348
Abstract: ABSTRACT Introduction Direct-acting SARS-CoV-2 antiviral monoclonal antibodies have been an integral part of therapeutic strategies against COVID-19 pandemic. The monoclonal strategy was jeopardized by the emergence of new variants and resistant strains, making many monoclonal… read more here.
Keywords: tixagevimab; development; cilgavimab; world evidence ... See more keywords
Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Transplantation"
DOI: 10.1111/ajt.17121
Abstract: The cilgavimab−tixagevimab combination retains a partial in vitro neutralizing activity against the current SARS‐CoV‐2 variants of concern (omicron BA.1, BA.1.1, and BA.2). Here, we examined whether preexposure prophylaxis with cilgavimab−tixagevimab can effectively protect kidney transplant… read more here.
Keywords: tixagevimab; tixagevimab 150; cilgavimab; kidney transplant ... See more keywords
Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2023.1139980
Abstract: Introduction The effect of tixagevimab/cilgavimab (Evusheld™; AstraZeneca, UK) should be evaluated in the context of concurrent outbreak situations. Methods For serologic investigation of tixagevimab/cilgavimab during the BA.5 outbreak period, sera of immunocompromised (IC) hosts sampled… read more here.
Keywords: tixagevimab; one month; tixagevimab cilgavimab; cilgavimab administration ... See more keywords